title: Immunohistochemical assessment of the MIB-1 Labeling Index in human hepatoblastoma and its prognostic relevance.
abstract: OBJECTIVE
  The MIB-1 monoclonal antibody has been raised against recombinant parts of the Ki-67 antigen, which is a cell cycle-related nuclear protein that is elevated in late G1 and S phases. The aim of the study was to analyze the expression pattern of MIB-1 in hepatoblastoma and to assess whether it provides any prognostic information in clinical practice.
  
  
  METHODS
  Sections from formalin-fixed paraffin embedded tissues were collected from 18 patients who had hepatoblastoma and stained with MIB-1 antibody according to streptavidinbiotin method. A percentage score of positively stained nuclei, MIB-1 Labeling Index (LI), was determined and correlated with clinical variables. MIB-1 LI ranged from 0% to 39.5% with a mean value of 13.5%. Among them in 14 patients, who received preoperative chemotherapy, the authors analyzed the result of MIB-1 staining.
  
  
  RESULTS
  Although there were no significant correlations between MIB-1 LI and age, sex, or histological type, a statistically significant correlation was found between clinical stage and MIB-1 LI. Mean MIB-1 LI was lower in patients with stage I and II than in those with stages III and IV (P < .05). Metastatic lesions showed higher MIB-1 LI than primary lesions, indicating that metastatic tumor cells have an increased rate of cellular proliferation. Kaplan Meier survival curve showed that patients with MIB-1 higher than 10% (n = 3) had a worse survival rate than those with lower than 10% MIB-1 LI (n = 11), whereas there was no significant difference because of the limited number of cases. Because high MIB-1 LI was correlated with clinical stage and poor survival rate, MIB-1 LI may be considered an important prognostic factor in hepatoblastoma.
  
  
  CONCLUSIONS
  Although further studies, including larger series of patients, are required, the authors consider MIB-1 immunostaining an easy method to assess proliferative activity that provides useful prognostic information in hepatoblastoma.
authors.affiliation: Department of Pediatric Surgery, Osaka University Medical School, and Research Institute for Maternal and Child Health, Suita City, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ara
authors.forename: M
authors.initials: M
authors.lastname: Fukuzawa
authors.forename: T
authors.initials: T
authors.lastname: Oue
authors.forename: Y
authors.initials: Y
authors.lastname: Komoto
authors.forename: T
authors.initials: T
authors.lastname: Kusafuka
authors.forename: K
authors.initials: K
authors.lastname: Imura
authors.forename: A
authors.initials: A
authors.lastname: Okada
mesh_terms: D000911:Antibodies, Monoclonal; D002455:Cell Division; D002648:Child; D002675:Child, Preschool; D005069:Evaluation Studies as Topic; D005260:Female; D018197:Hepatoblastoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D007223:Infant; D008113:Liver Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis
chemical_list: D000911:Antibodies, Monoclonal